September 4, 2026 · Journal of cardiac failure · DOI: 10.1016/j.cardfail.2026.08.019

Circulating Dipeptidyl Peptidase 3 levels, an Antagonist of Angiotensin-(1-7), in Acute Heart Failure: Insights from the PUSH-AHF trial

Listen to this summary

The authors aimed to investigate the levels of circulating dipeptidyl peptidase 3 (cDPP3) in patients with acute heart failure and their association with clinical characteristics, decongestive response, and outcomes. They found that higher cDPP3 concentrations were linked to impaired kidney function and reduced diuretic response, while natriuresis-guided therapy improved decongestion across different cDPP3 levels. The study suggests that further research is needed to clarify the clinical significance of cDPP3 in acute heart failure.

Stijn Legtenberg, Karine Santos, Iris E Beldhuis, Oliver Hartmann, Lara E E C Zonneveld, Peter van der Meer, Jan A Krikken, Wybe Nieuwland, Dirk J van Veldhuisen, Adriaan A Voors, Kevin Damman, Jozine M Ter Maaten

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play